TabletsMRP Under Process
Official PMBI MRP is being updated for catalog code 2833.
Locate Jan Aushadhi KendraClinical Overview
Methylphenidate Hydrochloride is a central nervous system stimulant on the WHO Model List of Essential Medicines. It acts by blocking the presynaptic dopamine transporter (DAT) and norepinephrine transporter (NET), substantially inhibiting reuptake and boosting synaptic catecholamine availability in the prefrontal cortex, enhancing sustained attention, impulse inhibition, and executive control. Indicated for Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally with water, in the morning (for extended-release) or divided morning and midday (for immediate-release), with or without meals. Do not take late in the afternoon or evening to avoid severe insomnia. Extended-release tablets must be swallowed whole without chewing or crushing.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Decreased appetite, weight loss, insomnia, dry mouth, nausea, abdominal pain, headache, tachycardia, palpitations. Rare/Severe: Boxed warning: High potential for abuse and dependence; sudden cardiac death in pre-existing cardiac defects, severe hypertension, priapism, peripheral vasculopathy (Raynaud's), and growth suppression in children.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black box warning: High abuse potential and dependence. Schedule X controlled substance in India; strict prescription records required. Contraindicated in severe anxiety/agitation, glaucoma, tics/Tourette's syndrome, and concurrent MAOIs. Monitor height, weight, blood pressure, and heart rate regularly in children.
Schedule X (Controlled Substance - Strict Prescription)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified pharmacist before initiating, modifying, or substituting any medication regimen.
Methylphenidate Tablet 10Mg
Methylphenidate Hydrochloride is a central nervous system stimulant on the WHO Model List of Essential Medicines. It acts by blocking the presynaptic dopamine transporter (DAT) and norepinephrine transporter (NET), substantially inhibiting reuptake and boosting synaptic catecholamine availability in the prefrontal cortex, enhancing sustained attention, impulse inhibition, and executive control. Indicated for Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy.
Methylphenidate Tablet 18Mg
Methylphenidate Hydrochloride is a central nervous system stimulant on the WHO Model List of Essential Medicines. It acts by blocking the presynaptic dopamine transporter (DAT) and norepinephrine transporter (NET), substantially inhibiting reuptake and boosting synaptic catecholamine availability in the prefrontal cortex, enhancing sustained attention, impulse inhibition, and executive control. Indicated for Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy.
Methylphenidate Tablet 20Mg
Methylphenidate Hydrochloride is a central nervous system stimulant on the WHO Model List of Essential Medicines. It acts by blocking the presynaptic dopamine transporter (DAT) and norepinephrine transporter (NET), substantially inhibiting reuptake and boosting synaptic catecholamine availability in the prefrontal cortex, enhancing sustained attention, impulse inhibition, and executive control. Indicated for Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy.